Avadel Pharmaceuticals plc (NASDAQ: AVDL), a clinical-stage biopharmaceutical company developing therapies for sleep disorders and neurologic conditions, is planning a $160 million initial public...
A New Blank Check Fund Enters the Energy Fray
Activate Energy Acquisition, a special purpose acquisition company (SPAC), has filed with the SEC for a...